“Great companies go through versions,” Sabry said. “They go through building their fundamental business in one direction. And then over time, these things change. That happened at Genentech. It’s happened to Roche, and it will happen to BioMarin as well.”

https://endpts.com/biomarins-james-sabry-talks-biotech-ma-dealmaking-in-2025/